{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:37:11Z","timestamp":1790012231548,"version":"4.0.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>SGLT2 inhibitors have a wide extent of restorative movement and higher chance of hypoglycemia because of their affront autonomous action in treating type 2 diabetes. SGLT2 inhibitors have great security and resistance when utilized as monotherapy or in conjunction with other oral hypoglycemic medicines. Since SGLT2 inhibitors can cause hyperglycemia, which results in vaginal and urinary tract infection contaminations. When compared, dapagliflozin had higher contaminations. The key issue displayed is that ketoacidosis and that it may take a little time to analyze it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>To compare the security of canagliflozin and dapagliflozin by watching the long-term impacts on the urinary volume, changes in renal status, and metabolic changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH METHODOLOGY:<\/jats:title>\n                    <jats:p>A Planned Interventional Comparative Ponder conducted among 1726 patients who were conceded to in the General Medicine and Endocrine Departments, Anu Group of hospitals, Vijayawada over 12 months from December 2021 to December 2022. By alluding to the patient\u2019s fasting blood sugar and postprandial blood sugar, renal function test, glycated hemoglobin, blood pressure, and the finding seriousness score of adverse drug reaction (ADR) utilizing Naranjo scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Patients had most common ADRs after utilizing Canagliflozin and Dapagliflozin, were hypotension and dehydration, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>We concluded that in patients had ADRs after utilizing Canagliflozin versus Dapagliflozin where hypotension and dehydration were more common, respectively. ADRs in the control population was weight pick up had the negative impact and hypoglycemia was found to be more in the control population compared to canagliflozin and dapagliflozin endorsed bunches. Weight loss had a positive impact on canagliflozin and dapagliflozin-endorsed groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_924_24","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:00:25Z","timestamp":1755864025000},"page":"329-333","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus"],"prefix":"10.4103","volume":"57","author":[{"given":"Dhanush","family":"Bellapu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Darwin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/clpt.2011.16","article-title":"Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus","volume":"89","author":"Pfster","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empaglifozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Efect of dapaglifozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitorsand mechanisms of cardiovascularbenefit: a state-ofthe-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"R6-20260421","doi-asserted-by":"crossref","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium\u2013glucose cotransporter-2 inhibitors: A review of spontaneous post marketing cases","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"R7-20260421","first-page":"411","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"NEJM"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_924_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:15Z","timestamp":1787837055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_924_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_924_24","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2024-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}